ArriVent BioPharma, Inc. (AVBP) Key Metrics
AVBP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $821.5M
- Enterprise value
- $1.12B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.35
AVBP key metrics, FY2021–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsAVBP valuation Price multiples at each fiscal year-end price.
AVBP returns How much profit the business earns on the capital it uses.
AVBP per-share figures Results divided by the shares outstanding at year-end.
AVBP financial health Debt, liquidity and how easily interest is covered.
AVBP valuation history
AVBP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AVBP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AVBP price vs earnings per share
AVBP key metrics
FY2021–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $709.6M | $739.5M | — | — | — |
| Enterprise value | $396.8M | $520.8M | — | — | — |
| Price / book | 2.3 | 2.9 | — | — | — |
| Earnings yield | −23.4% | −10.9% | — | — | — |
| Free cash flow yield | −22.6% | −9.5% | — | — | — |
| Share price at fiscal year-end | $18.45 | $23.50 | — | — | — |
| Per share | |||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$4.32 | −$2.56 | −$2.17 | −$1.10 | — |
| Operating cash flow per share | −$4.18 | −$2.23 | −$1.75 | −$1.30 | — |
| Free cash flow per share | −$4.18 | −$2.23 | −$1.75 | −$1.30 | — |
| Cash per share | $8.13 | $6.95 | $4.71 | $4.88 | — |
| Book value per share | $7.99 | $8.19 | $4.73 | $5.21 | — |
| Tangible book value per share | $7.99 | $8.19 | $4.73 | $5.21 | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Debt per share | $0.00 | $0.01 | $0.01 | $0.00 | — |
| Shares outstanding | 38.5M | 31.5M | 32.0M | 33.5M | — |
| Change in shares outstanding | +22.2% | −1.5% | −4.6% | — | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −58.9% | −39.4% | −42.6% | −34.2% | −125.2% |
| Return on invested capital (ROIC) | — | −370.7% | −946.3% | −384.4% | −174.3% |
| Return on assets (ROA) | −54.7% | −36.7% | −40.1% | −32.7% | −119.9% |
| Return on tangible assets | −49.9% | −29.3% | −42.5% | −20.2% | −119.9% |
| Financial health | |||||
| Total debt | $14,000 | $176,000 | $317,000 | $139,000 | — |
| Cash & short-term investments | $312.8M | $218.9M | $150.4M | $163.4M | $37.3M |
| Net debt | −$312.8M | −$218.7M | −$150.1M | −$163.2M | −$37.3M |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current ratio | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
| Quick ratio | 12.83 | 13.14 | 13.78 | 21.84 | 23.63 |
| Working capital | $307.0M | $209.7M | $148.3M | $174.3M | $41.1M |
| Invested capital | −$5.6M | $39.0M | $1.2M | $11.2M | $3.9M |
| Tangible asset value | $307.2M | $257.7M | $151.3M | $174.5M | $41.2M |
| Net current asset value | $307.0M | $209.7M | $148.2M | $174.3M | $41.1M |
| Graham net-net per share | $7.46 | $6.42 | $4.35 | $4.64 | — |
| Capital allocation | |||||
| Capex / depreciation | — | — | — | 0.00 | 0.00 |
| Efficiency | |||||
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $280,000 | $630,500 | $630,500 | $375,000 | $250,000 |
| Average payables | $4.9M | $4.2M | $3.8M | $1.7M | $293,000 |
| Average inventory | — | — | −$240,000 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from AVBP's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AVBP valuation and financial ratios
ArriVent BioPharma earned a return on equity of −58.9% in fiscal 2025. It ended the year with $0.0 million of debt and $312.8 million in cash and short-term investments, a net cash position of $312.8 million.
See the AVBP income statement, the AVBP chart for price history, or the AVBP stock overview for the latest quote and news.
AVBP key metrics FAQ
What is ArriVent BioPharma's return on equity?
ArriVent BioPharma's return on equity (ROE) was −58.9% in fiscal 2025: net income of -$166.3 million on average shareholders' equity of $282.4 million.
How much debt does ArriVent BioPharma have?
ArriVent BioPharma had total debt of $0.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is ArriVent BioPharma's free cash flow yield?
ArriVent BioPharma generated -$160.6 million of free cash flow in fiscal 2025, a free cash flow yield of −22.6% on its market value at year-end ($709.6 million).
What is ArriVent BioPharma's current ratio?
ArriVent BioPharma's current ratio was 12.83 at the end of fiscal 2025: current assets were 12.83 times current liabilities.